An interventional study of Additional semen samples in Hodgkin Disease Lymphoma, sponsored by Rennes University Hospital. Recruiting at 1 site in France. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Rennes University Hospital · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 72 studies in Hodgkin Disease with a site in France — 6 open to participants now, 13 under way, 2 of them phase 3. Hodgkin Disease · France.
Among the 72 studies in Hodgkin Disease with a site in France, this one is the 48th largest by planned enrollment of the 59 interventional ones that give a count, is the only one that started in 2026, is one of 13 with no phase, reaches primary completion later than 11 of the 12 other live ones, and was the 72nd registered.
1,384 studies on the registry are indexed under Hodgkin Disease; 160 are open to participants now.
Browse Hodgkin Disease studies →6 of the 72 studies in Hodgkin Disease with a site in France are open now. Recruiting first, the newest first:
AstraZeneca · Sites in France, United States, Australia and 8 more countries
Ages 12+
University Hospital, Clermont-Ferrand · Sites in France
Ages 18+
Hospices Civils de Lyon · Sites in France
Ages 18+
University Hospital, Montpellier · Sites in France
Ages 18+
Lille Catholic University · Sites in France
Ages 18–40 · Healthy volunteers
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 133 Hodgkin Disease studies recruiting now, 70 (53%) set no upper age limit and 51 (38%) stop at 75 or younger; 46 take children under 18; 10 take healthy volunteers.
This study: 18 Years to 45 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
72 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 27 · Phase 3 14
First in 1989; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 50 is above the median of 40 across 1,095 interventional studies indexed under Hodgkin Disease.
Median enrollment 106 across the 59 interventional studies, 171 across the 10 observational. Of the 52 that completed or were terminated, 17 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 72 have an industry lead sponsor. The 10 most frequent:
Rennes University Hospital is the lead sponsor of 451 studies on the registry; 51 are open to participants now.
Rennes University Hospital has 3 studies filed under Hodgkin Disease — fewer than ten, so there is no comparison to draw.
3 of the studies in Hodgkin Disease with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03407144Merck Sharp & Dohme LLCSafety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) | 2027-02-12 |
| NCT06116929Lille Catholic UniversityHodgkin's Disease and Chemotherapy Before 40 Years | 2027-07-01 |
| NCT03869619Hospices Civils de LyonREal World Data in LYmphoma and Survival in Adults | 2027-11-14 |
Add all 3 to your calendar (.ics) → With an account.
Among the 72 studies in Hodgkin Disease with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Cancer treatments can have long-term effects on fertility. In men, scientific studies suggest that the process of sperm formation (spermatogenesis) may be disrupted even years after recovery, with potential consequences not only for fertility but also for the health of offspring. The effects of chemotherapy on sperm quality, particularly on DNA packaging (chromatin) and the epigenome, remain poorly understood. Therefore, further in-depth studies are needed to determine whether a history of cancer and chemotherapy treatment may impact the health of children fathered by young male survivors.
We therefore propose to conduct a clinical study aimed at better understanding the mechanisms by which chemotherapies affect spermatogenesis. The results could provide answers by identifying the effects of these drugs on the fertility of young male cancer patients in the long term and the sperm epigenome indicative of the health of the progeny.
Advances in cancer treatments are raising new health questions for young survivors of the disease. Cancer itself and DNA-targeted treatments can have long-term effects on reproductive health. In men, spermatogenesis may remain impaired even years after recovery, with consequences for fertility and the health of offspring. It is important to note that sperm production can recover after cancer remission. However, men are advised to wait at least one year after the end of treatment before attempting natural conception, as gamete quality may influence reproductive capacity and offspring health. Yet, regardless of the mode of conception (natural or assisted reproduction), the question of whether a history of cancer and its treatment may affect the health of their offspring remains a fundamental issue that has not yet been clearly answered. In-depth studies are needed for this growing population of young cancer survivors who wish to have healthy children.
Where possible, the use of alkylating agents-known for their long-term systemic harmful effects-is being reduced, and less reprotoxic compounds, such as anthracyclines, are favored. Anthracyclines are widely used to treat various cancers prevalent in young men with a favorable survival prognosis and are classified as weakly reprotoxic (i.e., causing a temporary reduction in sperm count). However, they are suspected of having long-term effects on sperm chromatin and epigenome. The establishment of the sperm epigenome is a complex process resulting from multiple nuclear events during spermatogenesis, including chromatin remodeling and compaction that occur during spermiogenesis. These represent windows of opportunity for alteration by xenobiotics. Furthermore, genomic regions undergoing chromatin rearrangements may be more vulnerable to alterations; if these regions are located on key genes for embryonic development or fetal programming, they may predict adverse effects on offspring. In fact, emerging evidence suggests that sperm epigenetic marks could be used clinically to predict fertility and male-mediated developmental toxicity.
Here, we focus on young men with Hodgkin lymphoma (HL), one of the most commonly diagnosed malignant tumors at a young age, with a good prognosis and low risk of relapse, and for which treatment is well characterized using an anthracycline-containing protocol: doxorubicin. This pathology thus represents a large and relevant population of young cancer survivors who will consider parenthood after cancer. Due to interindividual variability, human studies aiming to determine the effects of chemotherapy must be able to compare samples before and after treatment in the same individual. Such published prospective longitudinal studies are rare and often include very few cases, as they require substantial resources, strong links between oncology and reproduction services, and the ability to follow patients over time, even after the end of oncological treatment. A (non-longitudinal) study of the long-term effects of HL treatments demonstrated persistent abnormalities in chromatin structure and DNA integrity. In the study proposed here, we will analyze epigenetic modifications in sperm from HL patients and their evolution after chemotherapy. We hypothesize that HL and its treatment induce persistent alterations up to 2 years after remission.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
30 men with hodgkin lymphoma will be followed during 24 months in order to search epigenetic modifications in male gametes
Other: Additional semen samples
5 additional semen samples : before chemotherapy, at month 6, 12, 18 and 24 after chemotherapy. Each sperm sample will be stored in liquid nitrogen and sent to Institut National de la Recherche Scientifique (INRS), Quebec, Canada for epigenetic analysis.
Alterations in DNA methylation patterns in spermatozoa
Sperm analysis : Methyl-C Capture Sequencing (MCC-seq)
Time frame: Before chemotherapy, month 6, month 12, month 18, month 24 after chemotherapy
Alterations of histone 3 H3k4me3 retention sites in spermatozoa
Sperm analysis : chromatin immunoprecipitation followed by sequencing (ChIP-seq)
Time frame: Before chemotherapy, month 6, month 12, month 18, month 24 after chemotherapy
Spermogram exam
Spermogram examination
Time frame: Before chemotherapy, month 6, month 12, month 18, month 24 after chemotherapy
Identification of known environmental factors impacting spermatogenesis
Patient questionnaire
Time frame: Month 24 after chemotherapy
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2026 (actual). Primary completion is estimated for Nov 2030, 48 months after the start.
Of 50 non-industry interventional studies with no phase under Hodgkin Disease, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 128. This study's planned 48 months is above that.
Counting every sponsor, half of 53 studies reached it within 42 months; a quarter within 29 and three quarters within 128.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: start Jun 2026 → Nov 2026, primary completion Jan 2030 → Nov 2030 and completion Jan 2030 → Nov 2030.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.